A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|20|3622-3630

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.20, 2015-10, pp. : 3622-3630

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : 179-186

John Wiley & Sons Inc

Access to resources Recommend Favorite

High-Dose Idarubicin, Busulphan and Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma Responsive to DAV Chemotherapy: Comparison with a Historical Control

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 9-14

Karger

Access to resources Recommend Favorite

Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer

By  

Oncology, Vol. 83, Iss. 2, 2012-06 ,pp. : 57-66

Karger

Access to resources Recommend Favorite

Outcomes of primary refractory multiple myeloma and the impact of novel therapies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 981-985

John Wiley & Sons Inc

Access to resources Recommend Favorite

Very Low Doses of Thalidomide as Single Agent in Relapsed/Refractory Multiple Myeloma

By  

Acta Haematologica, Vol. 116, Iss. 1, 2006-07 ,pp. : 70-71

Karger

Access to resources Recommend Favorite